# EDGAR Filing Document

**Accession Number:** 0001135951
**File Stem:** 0001575872-25-000750
**Filing Date:** 2025-12
**Character Count:** 16332
**Document Hash:** b6b6185467aafc1f5ef223e2f055df35
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001575872-25-000750.hdr.sgml**: 20251208

**ACCESSION NUMBER**: 0001575872-25-000750

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20251208

**FILED AS OF DATE**: 20251208

**DATE AS OF CHANGE**: 20251208

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DR REDDYS LABORATORIES LTD
- **CENTRAL INDEX KEY:** 0001135951
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** K7
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15182
- **FILM NUMBER:** 251555089

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 8-2-337, ROAD NO.3 BANJARA HILLS
- **CITY:** HYDERABAD
- **PROVINCE COUNTRY:** K7
- **ZIP:** 500-034
- **BUSINESS PHONE:** 91 40 49002900

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 8-2-337, ROAD NO.3 BANJARA HILLS
- **CITY:** HYDERABAD
- **PROVINCE COUNTRY:** K7
- **ZIP:** 500-034

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

Form 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**December, 2025**

**Commission File Number 1-15182**

## DR. REDDY'S LABORATORIES LIMITED
(Translation of registrant's name into English)

**8-2-337, Road No. 3, Banjara Hills**

**Hyderabad, Telangana 500 034, India**

**+91-40-49002900**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ◻&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No ⌧

If "Yes" is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

**EXHIBITS** 

---

| | |
|:---|:---|
| **Exhibit<br>Number**<br>| **Description of Exhibits** |
| [99.1](rdy0828_ex99-1.htm) | [Intimation dated December 08, 2025](rdy0828_ex99-1.htm) |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | DR. REDDY'S LABORATORIES LIMITED<br>(Registrant) | DR. REDDY'S LABORATORIES LIMITED<br>(Registrant) | DR. REDDY'S LABORATORIES LIMITED<br>(Registrant) |
| Date: December 08, 2025  | By: | /s/ K Randhir Singh | /s/ K Randhir Singh |
|  |  | Name: | K Randhir Singh |
|  |  | Title: | Company Secretary  |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| ![](rdy0828_ex99-1img01.jpg)<br>| **Dr. Reddy's Laboratories Ltd.**<br>8-2-337, Road No. 3, Banjara Hills<br>Hyderabad – 500 034, Telangana, India <br>CIN: L85195TG1984PLC004507<br>Tel:&nbsp;&nbsp;&nbsp;&nbsp; + 91 40 4900 2900<br>Fax:&nbsp;&nbsp;&nbsp;&nbsp; + 91 40 4900 2999<br>Email: <u>mail@drreddys.com</u><br>Web: <u>www.drreddys.com</u> |

---

December 8, 2025

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/ Madam,

**Ref: <u>Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")</u>**

This is to inform you that Dr. Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited ("Dr. Reddy's") has entered into a strategic collaboration and exclusive Licensing agreement with Immutep SAS, a wholly-owned subsidiary of Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep") to develop and commercialize Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China.

The details as required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are as hereunder:

---

| | | |
|:---|:---|:---|
| 1 | Name of the entity(ies) with whom agreement/ JV is signed | Immutep SAS |
| 2 | Area of agreement/ JV | Licensing of Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China.  |
| 3 | Domestic/ international | Domestic and International. |
| 4 | Share exchange ratio/ JV ratio | Not applicable. |
| 5 | Scope of business operation of agreement/ JV | Through this deal, Dr. Reddy's gets an exclusive right to develop and commercialize Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China. |
| 6 | Details of consideration paid/ received in agreement/ JV | Under the terms, Immutep to receive upfront payment of USD 20 million (~AUD 30.2 million) and is also eligible to receive potential regulatory development and commercial milestones payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales. |
| 7 | Significant terms and conditions of agreement/ JV in brief | Under the terms of the agreement, Immutep grants Dr. Reddy's an exclusive license, with the right to grant sublicense to develop, register and commercialize Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China. |
| 8 | Whether the transaction would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length | Immutep is not a related party to Dr. Reddy's or any of its promoter/promoter group/ group companies Therefore, this transaction with Immutep does not fall<br>within related party transactions. Further, promoter/promoter group/ group companies do not have any interest in Immutep. |
| 9 | Size of the entity(ies) | Not applicable. |
| 10 | Rationale and benefit expected | Through this Licensing agreement, Dr. Reddy's marks its continuous efforts to deliver first-in-class and innovative therapies for cancer treatment. Eftilagimod alfa is a novel immunotherapy with the potential to set a new standard of care in combination with anti-PD-[L]1 and chemotherapy as first-line therapy for non-small cell lung cancer. Eftilagimod Alfa's broad potential extends to other major cancers across multiple stages of disease. Through this agreement, Dr. Reddy's looks forward to leveraging expertise and strong market access to advance the development and commercialization of this promising cancer therapy across multiple markets. |

---

A press release to be issued in relation to the above matter is enclosed for reference.

This is for your information and records.

Thanking you.

Yours faithfully,

For **Dr. Reddy's Laboratories Limited**

**K Randhir Singh**

Company Secretary, Compliance Officer & Head-CSR

Encl: As above

**Immutep and Dr. Reddy's Enter into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa** 

· *Dr. Reddy's receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China* 

· *Under the terms, Immutep to receive upfront payment of USD 20 million (~AUD 30.2 million) and is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales* 

**Sydney, Australia/Hyderabad, India- December 08, 2025 –** <u>Immutep Limited</u> (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases and <u>Dr. Reddy's Laboratories Ltd</u>., (BSE: 500124 \| NSE: DRREDDY \| NYSE: RDY \| NSEIFSC: DRREDDY, and along with its subsidiaries, hereafter referred to as "Dr. Reddy's"), today announced that their respective wholly-owned subsidiaries, Immutep SAS and Dr. Reddy's Laboratories SA, have entered into a strategic collaboration and exclusive licensing agreement for the development and commercialisation of Eftilagimod Alfa (efti) in all countries outside North America, Europe, Japan, and Greater China.

Efti is Immutep's first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Efti is also being investigated in other indications including head & neck cancer, breast cancer, and soft tissue sarcoma.

The terms of the licensing agreement provide Immutep significant milestones and preserve its ability to capture material future upside in the licensed markets as efti advances commercially. Further, Immutep holds the global manufacturing rights to the product across all markets and will supply the product to Dr. Reddy's in the licensed markets, while Immutep retains all rights to the product in the key pharmaceutical markets, including North America, Europe, and Japan.

Additionally, as per the agreement, Immutep will receive from Dr. Reddy's an upfront payment of USD 20 million (~AUD 30.2 million). It is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales in these markets.

"This collaboration marks our continuous efforts to deliver first-in-class and innovative therapies for cancer treatment. Efti is a novel immunotherapy with the potential to set a new standard of care in combination with pembrolizumab (Keytruda®) and chemotherapy as first-line therapy for non-small cell lung cancer. Its broad potential extends to other major cancers across multiple stages of disease. Through this agreement, we look forward to leveraging our expertise and strong market access to advance the development and commercialization of this promising cancer therapy in the licensed markets," stated **M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy's.** 

"This agreement with Dr. Reddy's marks a significant milestone for Immutep and further validates the potential of efti. Dr. Reddy's proven capabilities and reach in the licensed markets make them an ideal partner to maximise the impact of our innovation and serve a large number of patients across the globe. Additionally, this partnership allows us to capture significant value for efti in the licensed markets, while retaining full rights in key markets such as North America, Europe, and Japan, and ensures we remain very well-positioned for future value creation," said **Marc Voigt, CEO of Immutep.**

![](rdy0828_ex99-1img02.jpg)<br>

**About Eftilagimod Alfa (Efti):**

Efti is a first-in-class soluble LAG-3 protein and MHC Class II agonist delivered subcutaneously that uniquely activates antigen-presenting cells or APCs (e.g., dendritic cells, monocytes) via major histocompatibility complex (MHC) class II ligands. As an MHC Class II agonist, its activation of APCs engages the adaptive and innate immune system to initiate a broad anti-cancer immune response. This includes priming and activating cytotoxic T cells as well as generating important co-stimulatory signals & cytokines that further boost the immune system's ability to combat cancer.

Efti is under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC) in a pivotal Phase III trial called TACTI-004 (KEYNOTE-F91), as well as head and neck squamous cell carcinoma (HNSCC), soft tissue sarcoma, and breast cancer. Its favourable safety profile enables various combinations like with anti-PD-[L]1 immunotherapy, radiotherapy, and/or chemotherapy. This has been demonstrated across early-stage trials in NSCLC and HNSCC, which have laid the foundation for the larger randomized clinical trial in NSCLC. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA).

**About Dr. Reddy's:**

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', Dr. Reddy's offers a portfolio of products and services including APIs, generics, branded generics, biosimilars, innovative drugs, and OTC. Our major therapeutic areas of focus are oncology, gastroenterology, cardiology, diabetology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has led to several industry firsts, Dr. Reddy's continues to plan and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: <u>www.drreddys.com</u>

**About Immutep:**

Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and *autoimmune disease.* The Company is a pioneer in the understanding and advancement of therapeutics related to **Lymphocyte Activation Gene-3** (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <u>www.immutep.com.</u>

*KEYTRUDA<sup>®</sup> is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.*

**Immutep Contacts:**

**Australian Investors/Media:**

Eleanor Pearson, Sodali & Co.

+61 2 9066 4071; <u>eleanor.pearson@sodali.com</u>

**U.S. Investors/Media:**

Chris Basta, VP, Investor Relations and Corporate Communications

+1 (631) 318 4000; <u>chris.basta@immutep.com</u>

**<u>Dr. Reddy's Contacts:</u>**

---

| | |
|:---|:---|
| **Media Relations:**<br>Priya K<br><u>priyak@drreddys.com</u> | **Investors Relations:**<br>Aishwarya Sitharam<br><u>aishwaryasitharam@drreddys.com</u> |

---

<br>